Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease
| Autor: | Jonathan Vogelgsang, Rebekka Vogelgsang, Jens Wiltfang, Hedieh Shahpasand-Kroner, Ruth Vukovich, Frank Streit |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Neurology Neuropathology Gastroenterology Diagnosis Differential 03 medical and health sciences blood [Alzheimer Disease] Sex Factors 0302 clinical medicine Cerebrospinal fluid Internal medicine blood [Amyloid beta-Peptides] medicine Humans Dementia ddc:610 Aged Aged 80 and over blood [Biomarkers] Amyloid beta-Peptides business.industry methods [Immunoassay] General Neuroscience diagnosis [Alzheimer Disease] amyloid beta-protein (1-40) Middle Aged amyloid beta-protein (1-42) medicine.disease blood [Dementia] Peptide Fragments diagnosis [Dementia] 030104 developmental biology blood [Peptide Fragments] Biomarker (medicine) Female Liver function Alzheimer's disease business Biomarkers 030217 neurology & neurosurgery Blood sampling |
| Zdroj: | Experimental brain research 236(5), 1241-1250 (2018). doi:10.1007/s00221-018-5210-x |
| ISSN: | 1432-1106 0014-4819 |
| DOI: | 10.1007/s00221-018-5210-x |
| Popis: | The cerebrospinal fluid (CSF) biomarkers amyloid-β42 (Aβ42), total Tau, and phospho-181-Tau represent important diagnostic tools to support the clinical diagnosis of Alzheimer's disease (AD). Acquiring CSF by lumbar puncture is considered a moderately invasive procedure, while blood sampling is minimally invasive with calculable risks and can be performed by trained non-medical staff. Thus, the identification of reliable and robust blood biomarkers of AD-related neuropathology would be significantly advantageous in daily practice and would allow more patients to be screened. In this study, we performed a multiplex amyloid-β assay to simultaneously measure Aβ40 and Aβ42. We analyzed how well Aβ40, Aβ42, and the Aβ42 to Aβ40 ratio (Aβ42/40) could differentiate between patients suffering from dementia either due or not due to AD. In addition, we studied different factors affecting Aβ levels in plasma. Plasma Aβ42/40 level was significantly lower in patients with dementia due to AD than in those with dementia due to other causes. Aβ42/40 correlated weakly between plasma and CSF, but did not differ between amyloid-PET positive or negative patients. Furthermore, we found that kidney function influences Aβ40 and Aβ42 plasma levels, but not Aβ42/40 level. Liver function, age, and sex do not affect Aβ levels in plasma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink